Drugs / Cefuroxime
Cefuroxime
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ZINACEF | — | 1983-10-19 | fda.gov ↗ |
Trials 29
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT06406114 | May 2025 → Jul 2028 expected | anaphylaxis, drug allergy, drug pseudoallergy | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05398081 | Dec 2021 → Feb 2022 | — | Dr. Promise Tamunoipiriala Jaja | Completed | No outcome recorded |
| Phase 2 | NCT03935828 | Jun 2019 → Dec 2020 | chronic rhinosinusitis, poisoning | United States Naval Medical Center, San Diego | Withdrawn | No outcome recorded |
| Phase 2 | NCT02445859 | Aug 2015 → May 2017 | — | University of Leeds | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT05502380 | Sep 2022 → Dec 2024 overdue | bacterial infectious disease | Balgrist University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT02795949 | Oct 2016 → Jan 2020 | bacterial infectious disease | Andalusian Public Foundation for Health Research in Seville | Completed | Met primary |
| Phase 3 | NCT01524081 | Jul 2008 → Jul 2011 | appendicitis, intestinal obstruction, peptic ulcer perforation | The Faculty Hospital Na Bulovce | Completed | No outcome recorded |
| Phase 412 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT06709196 | Jan 2025 → Jan 2027 expected | urinary bladder cancer | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 4 | NCT06766461 | Jan 2025 → Dec 2026 expected | infectious disease with sepsis | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06527560 | Sep 2024 → Dec 2027 expected | pyelonephritis | Hospital de Clinicas de Porto Alegre | Recruiting | No outcome recorded |
| Phase 4 | NCT05784311 | Mar 2023 → Jul 2025 overdue | malignant pancreatic neoplasm | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT04378868 | May 2020 → Jan 2023 | appendicitis | Helsinki University Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03108690 | Oct 2017 → Mar 2023 | bacterial infectious disease | Sara Thønnings | Withdrawn | No outcome recorded |
| Phase 4 | NCT03141476 | Mar → Nov 2017 | obesity disorder | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Phase 4 | NCT02819570 | Nov 2015 → Dec 2017 | preterm premature rupture of the membranes | Western Galilee Hospital-Nahariya | Unknown | Met primary |
| Phase 4 | NCT00901628 | Apr 2008 → Mar 2009 | osteoarthritis, knee | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00497341 | Jan 2008 → Aug 2010 | infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT01138852 | Jul 2004 → Dec 2008 | — | Attikon Hospital | Completed | Missed primary |
| Phase 4 | NCT00530400 | Apr 1994 → Mar 2000 | — | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase not applicable10 trials · 1 met primary | ||||||
| — | NCT06849037 | Feb 2025 → Feb 2027 expected | chorioamnionitis | Western Galilee Hospital-Nahariya | Recruiting | No outcome recorded |
| — | NCT07554079 | Feb 2024 → Nov 2025 | — | Kathmandu University School of Medical Sciences | Completed | No outcome recorded |
| — | NCT04723472 | Aug 2023 → Dec 2025 | Helicobacter pylori infectious disease | Shanghai East Hospital | Suspended | No outcome recorded |
| — | NCT05577273 | Aug 2018 → Aug 2023 | urinary tract infection | Omri Schwarztuch Gildor | Unknown | No outcome recorded |
| — | NCT02916134 | Sep 2016 → Dec 2019 | appendicitis | Beaumont Hospital | Completed | No outcome recorded |
| — | NCT01259141 | Oct 2010 → Dec 2014 | Mycoplasma pneumoniae pneumonia | Capital Medical University | Completed | No outcome recorded |
| — | NCT00355602 | Jul 2006 → Dec 2008 | ulcerative colitis | University of Dundee | Completed | No outcome recorded |
| — | NCT00162604 | May 2005 → ? | pelvic organ prolapse, prolapse of female genital organ | Hvidovre University Hospital | Unknown | No outcome recorded |
| — | NCT00136344 | Sep 2003 → May 2006 | endophthalmitis | City, University of London | Completed | Met primary |
| — | NCT00713999 | Aug 2001 → Apr 2002 | sexually transmitted disease, urinary schistosomiasis | University of Aarhus | Completed | No outcome recorded |
| Comparator or background therapy35 trials | ||||||
| Phase 0 | NCT04479657 Background | Oct 2020 → Dec 2023 | bacterial infectious disease, respiratory tract infectious disorder | Zhong Wang | Unknown | No outcome recorded |
| Phase 0 | NCT02789579 Background | Sep 2016 → Dec 2019 | — | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04212078 Comparator | Jul 2019 → Jan 2022 | endophthalmitis | National University of Malaysia | Unknown | No outcome recorded |
| Phase 2 | NCT07492134 Comparator | Jul 2026 → Apr 2028 expected | diverticulitis | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05609240 Comparator | May 2023 → May 2025 | — | University of Leeds | Unknown | No outcome recorded |
| Phase 2/3 | NCT04009772 Comparator | Jul 2019 → Feb 2020 | skin infection | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT00648726 Comparator | Jan → Aug 2003 | pneumonia | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT07236944 Comparator | Dec 2025 → Mar 2029 expected | bacterial urinary tract infection | Uppsala University | Recruiting | No outcome recorded |
| Phase 4 | NCT06351891 Background | Apr → Dec 2024 | Helicobacter pylori infectious disease | Qilu Hospital of Shandong University | Unknown | Met primary |
| Phase 4 | NCT05157113 Comparator | May 2022 → Apr 2025 | cataract | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT04161599 Background | Mar 2022 → Jun 2024 | — | Hospital Universitari Vall d'Hebron Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT03716804 Comparator | Jun → Dec 2018 | bacterial infectious disease, urinary tract infection | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 4 | NCT04303390 Comparator | Feb 2018 → May 2022 | — | Saud Al Babtain Cardiac Center | Completed | No outcome recorded |
| Phase 4 | NCT02505581 Background | May 2015 → Apr 2017 | — | Hospital Universitari Vall d'Hebron Research Institute | Completed | Met primary |
| Phase 4 | NCT02009098 Comparator | Oct 2014 → Oct 2015 | puerperal infection | Odense University Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT02072798 Comparator | Feb → Jul 2014 | puerperal infection | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01659866 Comparator | Aug 2012 → Aug 2015 | infectious disease | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT00818610 Background | Jan 2009 → Jan 2013 | pneumonia | Swiss National Fund for Scientific Research | Completed | No outcome recorded |
| Phase 4 | NCT01080963 Comparator | Nov 2008 → Mar 2012 | skin infection | Hannover Medical School | Completed | No outcome recorded |
| Phase 4 | NCT03877289 Background | Oct 2008 → Jul 2014 | cystitis | University of Calgary | Completed | No outcome recorded |
| Phase 4 | NCT00613769 Comparator | Sep 2007 → Dec 2011 | — | Halmstad County Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02436083 Comparator | Jul 2007 → Jun 2012 | — | Technical University of Munich | Completed | No outcome recorded |
| — | NCT07346742 Comparator | Mar 2025 → Feb 2026 overdue | hydrocele | Olawumi Olajide | Recruiting | No outcome recorded |
| — | NCT05337566 Background | Sep 2022 → Dec 2027 expected | — | Helsinki University Central Hospital | Recruiting | No outcome recorded |
| — | NCT03657836 Background | Aug 2018 → Jan 2019 | bronchitis | Nazarbayev University Medical Center | Completed | No outcome recorded |
| — | NCT02800785 Comparator | May 2016 → Mar 2020 | appendicitis | University of Washington | Completed | No outcome recorded |
| — | NCT02515565 Background | Sep 2015 → Apr 2018 | pneumonia | University of Granada | Unknown | No outcome recorded |
| — | NCT02169856 Background | Jul 2013 → Feb 2014 | — | Benazir Bhutto Hospital, Rawalpindi | Completed | No outcome recorded |
| — | NCT02162134 Background | Jan 2013 → Feb 2014 | ileus | Benazir Bhutto Hospital, Rawalpindi | Completed | No outcome recorded |
| — | NCT01507974 Comparator | Jan 2012 → Jul 2014 | pregnancy disorder | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT01372371 Comparator | Jun 2011 → Jun 2012 | infectious disease | Ganga Hospital | Unknown | No outcome recorded |
| — | NCT01237730 Comparator | Jul 2010 → Jul 2011 | — | National Cheng Kung University | Unknown | No outcome recorded |
| — | NCT00730938 Comparator | Feb → Jul 2008 | cataract, endophthalmitis | Presbyterian Church East Africa Kikuyu Hospital | Completed | No outcome recorded |
| — | NCT00492973 Background | Mar 2006 → Feb 2008 | osteoarthritis, knee | New Lexington Clinic | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 65 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cefuroxime | “Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile,...” NCT03877289 ↗62“Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until...” NCT02515565 ↗ “Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and...” NCT00713999 ↗ “If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg...” NCT02916134 ↗ “standard prophylaxis with cefuroxime versus a broad-spectrum prophylaxis of a combined single-shot of vancomycin 1 g and gentamicin 5 mg/kg parenterally” PMID 38243311 ↗ Jan 2024 “standard to double dosing of beta-lactam antibiotics (cefuroxime, ceftazidime, ceftriaxone, cefotaxime, amoxicillin, amoxicillin/clavulanic acid,” PMID 40119275 ↗ Mar 2025 “For oral antibiotics, the choices providers will be given include: Augmentin 500 mg every 12 hours, Cefuroxime 500 mg every 12 hours” NCT03935828 ↗ “bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline” NCT00492973 ↗ “Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.” NCT03657836 ↗ “Intraoperative intracameral injection of cefuroxime delivered at the end of surgery” NCT05157113 ↗ “Three postoperative doses of cefuroxime 750 mg; each dose eight hours apart” NCT07554079 ↗ |
| Known as | Cefuroxime "Fresenius Kabi" | “Cefuroxime "Fresenius Kabi"” NCT02072798 ↗1“Cefuroxime "Fresenius Kabi"” NCT02009098 ↗ |
| Known as | Cefuroxime Axetil | “single dose of P.O. Cefuroxime Axetil 500 mg.” NCT05577273 ↗ |
| Known as | zinacef | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06849037 ↗ |
| Known as | Zinacef 750mg (Cefuroxime 750mg, Glaxo Group Ltd., UK) | “Zinacef 750mg (Cefuroxime 750mg, Glaxo Group Ltd., UK)” NCT01524081 ↗ |
| Known as | Zinnat | “Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used” NCT05398081 ↗ |
| Action | Inhibit | “Following penetration of the bacterial cell surface, they attach to bacterial penicillin-binding proteins - proteins thay catalyze critical cell-wall synthesis and division...” NCT05398081 ↗ |
| Modality | Small molecule | “second generation cephalosporin” NCT04303390 ↗ |
| Route | Other | “intracameral cefuroxime injection” PMID 16631047 ↗ Mar 2006 |